How race and ethnicity affect outcomes for people with hormone receptor–positive breast cancer on CDK4/6 inhibitors
Impact of race and ethnicity on outcomes in patients with hormone receptor-positivebreast cancer treated with CDK4/6 inhibitors
['FUNDING_OTHER'] · BAYLOR COLLEGE OF MEDICINE · NIH-11143678
This project looks at why Black and Hispanic patients with hormone receptor–positive, HER2‑negative breast cancer may not be getting the same benefits from CDK4/6 inhibitor treatments as White patients.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | BAYLOR COLLEGE OF MEDICINE (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11143678 on ClinicalTrials.gov |
What this research studies
You would be part of a project that combines medical records, genetic data, and social information to understand outcome differences for people with HR+/HER2‑negative breast cancer treated with CDK4/6 inhibitors. The team will analyze national datasets like All of Us and tumor genomics from TCGA and will examine genes linked to CDK4/6 resistance such as FAT1, FAT4, and RB1. They will also review medication-taking patterns and social determinants of health to see how these issues affect survival for African American, Hispanic, and European American patients. The aim is to find biological or social reasons for unequal benefits so care can be tailored to improve results for all patients.
Who could benefit from this research
Good fit: Ideal participants are people diagnosed with hormone receptor–positive, HER2‑negative breast cancer—especially African American or Hispanic patients—who have taken or may take CDK4/6 inhibitors and can share medical records or genetic data.
Not a fit: People with other breast cancer subtypes (for example HER2‑positive or triple‑negative), those who never received CDK4/6 inhibitors, or those unwilling or unable to share clinical or genetic data are unlikely to benefit or participate.
Why it matters
Potential benefit: If successful, this work could help tailor treatments and support to reduce racial and ethnic gaps in survival for HR+/HER2‑negative breast cancer patients on CDK4/6 inhibitors.
How similar studies have performed: Population studies show survival gains after CDK4/6 inhibitors mainly for non‑Hispanic White patients and early genomic analyses suggest resistance‑related differences, but applying these findings to close racial gaps is a relatively new and active area of research.
Where this research is happening
HOUSTON, UNITED STATES
- BAYLOR COLLEGE OF MEDICINE — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PIYARATHNA, DANTHASINGHE WADUGE BADRAJEE — BAYLOR COLLEGE OF MEDICINE
- Study coordinator: PIYARATHNA, DANTHASINGHE WADUGE BADRAJEE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Breast Cancer, Breast Cancer Patient, Breast Cancer Treatment, Breast Cancer cell line